NCT04894682 (CoVac-Lung) is a clinical trial of Vaccine inoculation against SARS-CoV-2 in Lung Cancer, sponsored by Guangdong Provincial People's Hospital.

Who is sponsoring NCT04894682?

NCT04894682 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT04894682?

Interventions in NCT04894682: Vaccine inoculation against SARS-CoV-2.

What condition does NCT04894682 study?

NCT04894682 studies Lung Cancer, Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple, COVID-19 Pneumonia, Vaccine Adverse Reaction, SARS-CoV-2 Acute Respiratory Disease.

Is NCT04894682 still recruiting?

NCT04894682 is currently withdrawn. Last updated 17 March 2023.

Last reviewed 2023-03-17 · How we verify

NCT04894682: CoVac-Lung

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor

Withdrawn Last updated 17 March 2023

What this trial tests

trial testing Vaccine inoculation against SARS-CoV-2 in Lung Cancer. Withdrawn.

Timeline

4 May 2021

Primary endpoint
31 August 2021

31 May 2022

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	4 May 2021
Primary completion	31 August 2021
Estimated completion	31 May 2022
Sites	1 location across China

Drugs / interventions tested

Vaccine inoculation against SARS-CoV-2 — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Pulmonary Nodule, Solitary — all drugs for Pulmonary Nodule, Solitary →
Pulmonary Nodule, Multiple — all drugs for Pulmonary Nodule, Multiple →
COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →

Sponsor

Guangdong Provincial People's Hospital

Who can join

Adults 18 to 85, any sex, with Lung Cancer or Pulmonary Nodule, Solitary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to assess the inoculation-related symptoms and long-term effects of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting. The investigators aim to provide high-quality evidence for the COVID-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Misconception contributed to COVID-19 vaccine hesitancy in patients with lung cancer or ground-glass opacity: a cross-sectional study of 324 Chinese patients.
Zhuang W, Zhang J, Wei P, Lan Z, et al · · 2021 · cited 16× · PMID 34715002 · DOI 10.1080/21645515.2021.1992212
An Impact of COVID-19 on Cancer Care: An Update.
Chavda VP, Ping FF, Chen ZS. · · 2022 · cited 3× · PMID 36560482 · DOI 10.3390/vaccines10122072

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04894682 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 17 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04894682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing